A previously healthy 63-year-old woman, unvaccinated for influenza A, had a mild fever for a week followed by alerted consciousness. On the day of admission, she developed shortness of breath, high fever, hypotension and alterations of consciousness. Chest CT revealed rapidly progressing bilateral infiltrates.
View Article and Find Full Text PDFIntroduction: Immune-checkpoint inhibitors, such as pembrolizumab, have been used for non-small cell lung cancer treatment but are often associated with immune-related adverse events (irAEs).
Case Presentation: A 71-year-old female was diagnosed with lung adenocarcinoma (cT3N0M1c; BRN, cStage IVB [UICC-8th edition]) and was treated with pembrolizumab monotherapy, achieving a partial response. After five cycles, she developed anorexia and abdominal pain, and upper gastrointestinal endoscopy revealed hemorrhagic gastritis because of irAEs.